Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients

Inclusion Criteria:

1. Medically able and willing to consent to study requirements

2. Adult, male and female burn patients

3. Ages 18 to 60 years of age

4. Able to understand the study requirements and consent without a translator

5. Have a BMI between 15 and 35 kg/m2 (inclusive)

6. Have clinically acceptable results in the safety laboratory tests as deemed by theinvestigator

7. Have full thickness burn injury that requires partial thickness skin graft (meshed)for any location other than the face and genitalia

8. Meshed skin graft size is between 50 cm2 and 800 cm2

9. Maximum skin graft expansion ratio is 1:1.5

10. Able to apply the IPs as instructed, whether by the participants themselves or theiraccompanying caregivers

Exclusion Criteria:

1. Medically unable to consent to study requirements

2. Treatment site(s) (skin graft site) located on the face and genitalia

3. Treatment site(s) (skin graft site) take more than 14 days after the skin graftsurgery to reach complete re-epithelization, based on the investigator's assessment

4. Expected to be medically unstable for the duration of the study period and anadditional 1-month thereafter

5. Pregnant, or attempting to become pregnant

6. Subjects who had taken part in an interventional clinical trial within 3 monthsprior to admission to this trial or who are currently participating in a clinicaltrial, whether an investigational drug was used or not

7. Subjects who had any clinical evidence of severe ongoing or prolonged depression ormental illness within the last year

8. Subjects who smoke more than 20 cigarettes a day

9. Subjects who have a history of heavy drinking in the past month, defined as morethan 14 drinks per week for men or more than 7 drinks per week for women

10. Subjects who have a history of substance abuse in the 12 months prior to screening (including having been hospitalized for such in an in-patient or out-patientintervention)

11. Subjects with severe inhalation injury requiring FiO2 >50%, renal failure requiringdialysis or hemodynamic instability requiring vasopressor therapy at the time ofinitiation of study treatment

12. Subjects who have scarring from previous interventions or evidence of thermal,electrical or radiation burn scars, tattoos, birthmarks or moles within 5 cm of thetreatment sites

13. Subjects with a history of abnormal keloid scarring

14. Subjects with additional concurrent illnesses or conditions that may have interferedwith wound healing like neoplastic, immune-mediated, or primary infectious disease (e.g. carcinoma, vasculitis, connective tissue disease, immune system disorders,uncontrolled HIV infection, rheumatoid arthritis, chronic renal impairment,significant hepatic impairment, inadequately or uncontrolled congestive heartfailure or diabetes mellitus) or any clinically significant medical condition orhistory of any condition which may impair wound healing

15. Subjects with a skin disorder that is chronic or currently active and which theinvestigator considers will adversely affect the healing of acute wounds or willinvolve the areas to be examined in this trial (including psoriasis, dermatitis,eczema)

16. A history of radiotherapy to the study scar area

17. Subjects who have known sensitivities to any components of the IPs

18. Any other diagnosis, condition, physical or geographical limitation with theparticipant